Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study

Abstract

BackgroundMalignant peritoneal mesothelioma (MPM) is a rare and aggressive disease. Recently, focus has shifted toward a more aggressive and multimodal treatment approach. This study aimed to assess the patterns of care and survival for MPM patients in the Netherlands on a nationwide basis.MethodsThe records of patients with a diagnosis of MPM from 1993 to 2016 were retrieved from the Dutch Cancer Registry. Data regarding diagnosis, staging, treatment, and survival were extracted. Cox regression analyses and Kaplan–Meier survival curves were used to study overall survival.ResultsBetween 1993 and 2016, MPM was diagnosed for 566 patients. Overall, the prognosis was very poor (24% 1-year survival). The most common morphologic subtype was the epithelioid subtype (88%), followed by the biphasic (8%) and sarcomatoid (4%) subtypes. Surgical treatment has become more common in recent years, which most likely has resulted in improved survival rates. In this study, improved survival was independently associated with hyperthermic intraperitoneal chemotherapy (hazard ratio [HR], 0.33; 95% confidence interval [CI], 0.21–0.55) and surgery with adjuvant systemic chemotherapy (HR, 0.33; 95% CI, 0.23–0.48). Nonetheless, most patients (67%) do not receive any form of anti-cancer treatment.ConclusionThis study indicated that MPM still is a rare and fatal disease. The survival rates in the Netherlands have improved slightly in the past decade, most likely due to more aggressive treatment approaches and increased use of surgery. However, most patients still do not receive cancer-directed treatment. To improve MPM management, and ultimately survival, care should be centralized in expert medical centers.

The psychosocial impact of living with mesothelioma: Experiences and needs of patients and their carers regarding supportive care

“…On a global level, it is estimated that in 2018, mesothelioma caused about 25,500 deaths; however, not all countries report specific numbers of mesothelioma mortalities (Cancer Today, 2020;Odgerel et al, 2017). In general, mesothelioma affects the lining surrounding the lungs and the inside of the thoracic wall, but it can also affect other areas, such as the peritoneal surface or tunica vaginalis (de Boer et al, 2019). It is almost exclusively caused by exposure to asbestos minerals (Girgis et al, 2019).…”

Challenging Diagnostic Process for a Malignant Peritoneal Mesothelioma Patient With Ascites and Pleural Effusion: A Case Report and Review of the Literature

“…For inoperable or non-resectable patients, which are not suitable for the standard treatment, the guidelines recommend choosing SC treatment rather than palliative care ( 9 ). A recent study showed that better survival was independently associated with both the treatment combination of CRS plus HIPEC and surgery plus SC ( 17 ), although the overall survival of patients treated with SC plus CRS was approximately 1 year ( 18 ). If MPM patients cannot hold a beneficial prognostic factor, the treatment mode of CRS + HIPEC + adjuvant SC should be adopted ( 9 ).…”

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study

“…As a result, the US Food and Drug Administration (FDA) approved the combination of nivolumab and ipilimumab as first-line treatment for unresectable MPM 4. For malignant peritoneal mesothelioma (MPeM), the median OS is about 6 months 5. For a long time, treatment options were identical to those for MPM.…”